Natural History of Gastric Cancer

Observational Study of Gastric Cancer Patients Not Treated During Follow-Up

Seung Young Oh, Jeong Hwan Lee, Hyuk Joon Lee, Tae Han Kim, Yeon Ju Huh, Hye Seong Ahn, Yun Suhk Suh, Seong Ho Kong, Ga Hee Kim, Su Joa Ahn, Se Hyung Kim, Yunhee Choi, Han Kwang Yang

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. Patients and Methods: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. Results: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. Conclusions: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.

Original languageEnglish
Pages (from-to)2905-2911
Number of pages7
JournalAnnals of Surgical Oncology
Volume26
Issue number9
DOIs
StatePublished - 15 Sep 2019

Fingerprint

Stomach Neoplasms
Observational Studies
Endosonography
Tumor Burden
Endoscopy
Neoplasms
Therapeutics
Survival Rate
Tomography
Neoplasm Metastasis
Survival

Keywords

  • Doubling time
  • Gastric cancer
  • Natural history
  • Progression
  • Survival benefit

Cite this

Oh, Seung Young ; Lee, Jeong Hwan ; Lee, Hyuk Joon ; Kim, Tae Han ; Huh, Yeon Ju ; Ahn, Hye Seong ; Suh, Yun Suhk ; Kong, Seong Ho ; Kim, Ga Hee ; Ahn, Su Joa ; Kim, Se Hyung ; Choi, Yunhee ; Yang, Han Kwang. / Natural History of Gastric Cancer : Observational Study of Gastric Cancer Patients Not Treated During Follow-Up. In: Annals of Surgical Oncology. 2019 ; Vol. 26, No. 9. pp. 2905-2911.
@article{ea409f79bde548bd902c681c0b042dde,
title = "Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up",
abstract = "Background: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. Patients and Methods: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. Results: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2{\%} in stage I and 0{\%} in stage II, stage III, and stage IV. Conclusions: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.",
keywords = "Doubling time, Gastric cancer, Natural history, Progression, Survival benefit",
author = "Oh, {Seung Young} and Lee, {Jeong Hwan} and Lee, {Hyuk Joon} and Kim, {Tae Han} and Huh, {Yeon Ju} and Ahn, {Hye Seong} and Suh, {Yun Suhk} and Kong, {Seong Ho} and Kim, {Ga Hee} and Ahn, {Su Joa} and Kim, {Se Hyung} and Yunhee Choi and Yang, {Han Kwang}",
year = "2019",
month = "9",
day = "15",
doi = "10.1245/s10434-019-07455-z",
language = "English",
volume = "26",
pages = "2905--2911",
journal = "Annals of surgical oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

Oh, SY, Lee, JH, Lee, HJ, Kim, TH, Huh, YJ, Ahn, HS, Suh, YS, Kong, SH, Kim, GH, Ahn, SJ, Kim, SH, Choi, Y & Yang, HK 2019, 'Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up', Annals of Surgical Oncology, vol. 26, no. 9, pp. 2905-2911. https://doi.org/10.1245/s10434-019-07455-z

Natural History of Gastric Cancer : Observational Study of Gastric Cancer Patients Not Treated During Follow-Up. / Oh, Seung Young; Lee, Jeong Hwan; Lee, Hyuk Joon; Kim, Tae Han; Huh, Yeon Ju; Ahn, Hye Seong; Suh, Yun Suhk; Kong, Seong Ho; Kim, Ga Hee; Ahn, Su Joa; Kim, Se Hyung; Choi, Yunhee; Yang, Han Kwang.

In: Annals of Surgical Oncology, Vol. 26, No. 9, 15.09.2019, p. 2905-2911.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Natural History of Gastric Cancer

T2 - Observational Study of Gastric Cancer Patients Not Treated During Follow-Up

AU - Oh, Seung Young

AU - Lee, Jeong Hwan

AU - Lee, Hyuk Joon

AU - Kim, Tae Han

AU - Huh, Yeon Ju

AU - Ahn, Hye Seong

AU - Suh, Yun Suhk

AU - Kong, Seong Ho

AU - Kim, Ga Hee

AU - Ahn, Su Joa

AU - Kim, Se Hyung

AU - Choi, Yunhee

AU - Yang, Han Kwang

PY - 2019/9/15

Y1 - 2019/9/15

N2 - Background: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. Patients and Methods: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. Results: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. Conclusions: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.

AB - Background: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. Patients and Methods: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. Results: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. Conclusions: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.

KW - Doubling time

KW - Gastric cancer

KW - Natural history

KW - Progression

KW - Survival benefit

UR - http://www.scopus.com/inward/record.url?scp=85068052448&partnerID=8YFLogxK

U2 - 10.1245/s10434-019-07455-z

DO - 10.1245/s10434-019-07455-z

M3 - Article

VL - 26

SP - 2905

EP - 2911

JO - Annals of surgical oncology

JF - Annals of surgical oncology

SN - 1068-9265

IS - 9

ER -